Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through AKT-mTOR pathway.
Sarcoidosis vasculitis and diffuse lung diseases · 24.09.2024 · 41 (3) · e2024034-e2024034
DOI: 10.36141/svdld.v41i3.12728 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 24.09.2024. Verfasst von Jie Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine ,Wuhan Fourth Hospital, Wuhan, Hubei Province, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE: Schisandrin B (Sch B) is an active monomer of Schisandrin with anti-fibrosis pharmacological action. The study investigated whether Sch B alleviate bleomycin-induced (BLM-Induced) pulmonary fibrosis in mice and attempted to clarify its anti-fibrosis mechanism. METHODS: Histopathological examination was performed by H&E staining and immunohistochemistry. The inflammatory cytokines and oxidative stress were determined by ELISA. Western blotting and immunofluorescence were used to investigate the possible molecular mechanism to attenuate pulmonary fibrosis by Sch B. RESULTS: The results indicated that Sch B can significantly attenuate BLM-Induced pulmonary fibrosis, myofibroblast activation, and collagen fibers deposition in mice. In addition, Sch B can inhibit inflammatory response and oxidative stress in early stage. Furthermore, Sch B can inhibit pulmonary fibrosis by promoting autophagy via promoting the dephosphorylation of AKT-mTOR pathway. CONCLUSIONS: The results suggest that the anti-fibrotic effect of Sch B is potentially related to the activation of autophagy through AKT-mTOR pathway, and Sch B is a potential agent for the treatment of idiopathic pulmonary fibrosis.
Schlagwörter
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine ,Wuhan Fourth Hospital, Wuhan, Hubei Province, China.
- Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Zitieren
APA
Yang, J., Zhou, D., Hu, J., Yang, D. H., Cai, Y., & Lu, Q. (2024). Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through AKT-mTOR pathway. Sarcoidosis vasculitis and diffuse lung diseases, 41(3), e2024034-e2024034. https://doi.org/10.36141/svdld.v41i3.12728
Vancouver
Yang J, Zhou D, Hu J, Yang DH, Cai Y, Lu Q. Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through AKT-mTOR pathway. Sarcoidosis vasculitis and diffuse lung diseases. 2024;41(3):e2024034-e2024034. doi:10.36141/svdld.v41i3.12728
BibTeX
@article{Yang2024,
author = {Yang, Jie and Zhou, Dengfeng and Hu, Jianwu and Yang, David H and Cai, Yuanping and Lu, Qiaofa},
title = {Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through AKT-mTOR pathway},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2024},
volume = {41},
number = {3},
pages = {e2024034--e2024034},
doi = {10.36141/svdld.v41i3.12728}
}
EUVIMED